CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Dasatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02428855
NCT02428855Phase 2Completed
CompareCT.gov

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Massachusetts General Hospital·interventional·Posted Apr 29, 2015·Updated Jul 31, 2020

In Brief

A Phase 2 clinical trial evaluating Dasatinib for Cholangiocarcinoma. Completed, enrolled 8 participants across 2 sites.

Detailed Summary

This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholangiocarcinoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, TargetCancer Foundation

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 29, 2015
Enrollment StartApr 1, 2015
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.2 years ago

Interventions

Dasatinibdrug